Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomustine versus lomustine + bevacizumab in recurrent glioblastoma
2020-003545-11Phase 3Active
- Sponsor
- Rigshospitalet
- Start
- Aug 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in glioblastoma (GBM) comparing Lomustine monotherapy with Lomustine + bevacizumab (Zirabev) (2 arms). Primary endpoint: Overall survival. Started Aug 2020; status: active.
02
Drugs
bevacizumab-bvzrlomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2020-003545-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003545-11.